RxDoctor Payments Data

Courtney Mellen, APRN

Nurse Practitioner · Scottsdale, AZNPI 1861007122

Payments from drug & device makers

$1,409in general payments, 2019–2025

Across 16 payments — averaging $88.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Catalyst Pharmaceuticals, Inc.$602
  • Eisai Inc.$385
  • Johnson & Johnson$134
  • Delcath Systems$67
  • Bristol Myers Squibb$65
  • Incyte Corporation$65
  • plus $91 from 2 others

What the payments were for

  • Consulting fees$31522%
  • Speaking & faculty fees$52537%
  • Food & beverage$50436%
  • Education$655%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,409 in reported general payments places this provider in the 85th percentile of 1,719 nurse practitioner providers in Arizona.

See all nurse practitioner providers in Arizona

Medicare billing

Part B allowed, 2024
$37,099
Medicare patients
284
Services billed
478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide41$580,566
NubeqaDarolutamide22$283,968
CabometyxCabozantinib S-Malate11$247,704
XtandiEnzalutamide13$179,785
Abiraterone Acetate120$112,674
OrgovyxRelugolix14$37,586
Venlafaxine Hcl ErVenlafaxine Hcl26$638
Prednisone110$629
Betamethasone Dipropionate11$562
Levothyroxine Sodium14$253
Dexamethasone20$225
Tamsulosin Hcl21$184
Gabapentin16$154
Oxycodone Hcl18$147
Amlodipine Besylate36$113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$134$580,56641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,719 nurse practitioner providers in Arizona.

Other nurse practitioner in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →